Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ARA290 in no-option critical limb ischemia
2010-018584-41Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cibinetide in chronic limb-threatening ischemia (CLTI), sponsored by Leiden University Medical Center. Primary endpoint: Safety and tolerability of ARA290. Started Mar 2010; status: active.
02
Drugs
cibinetide
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2010-018584-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018584-41.